Altimmune, Inc. Earnings Per Share Diluted

• Altimmune, Inc. showed an increase of +25.4% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
• XBRL data for this metric is available from 2014 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2014: $0.04 (loss) per share | Q1 2015: $0.02 per share | Q2 2015: $0.04 (loss) per share | Q3 2015: $0.02 (loss) per share | Q4 2015: $0.02 (loss) per share | Q1 2016: $0.02 (loss) per share | Q2 2016: $0.12 per share | Q3 2016: $1.67 per share | Q4 2016: $1.15 per share | Q3 2020: $0.54 (loss) per share | Q1 2021: $0.38 (loss) per share | Q2 2021: $0.60 (loss) per share | Q3 2021: $0.81 (loss) per share | Q1 2022: $0.44 (loss) per share | Q2 2022: $0.42 (loss) per share | Q3 2022: $0.48 (loss) per share | Q1 2023: $0.40 (loss) per share | Q2 2023: $0.32 (loss) per share | Q3 2023: $0.39 (loss) per share | Q1 2024: $0.34 (loss) per share | Q2 2024: $0.35 (loss) per share | Q3 2024: $0.32 (loss) per share | Q1 2025: $0.26 (loss) per share | Q2 2025: $0.27 (loss) per share | Q3 2025: $0.21 (loss) per share.
• Over the full 9 years of available data (2014 to 2025), Altimmune, Inc.'s Earnings Per Share Diluted has declined by 488.2%.
• Historical annual values: Fiscal year 2025: $1.00 (loss) per share | Fiscal year 2024: $1.34 (loss) per share | Fiscal year 2023: $1.66 (loss) per share | Fiscal year 2022: $1.81 (loss) per share | Fiscal year 2021: $2.35 (loss) per share | Fiscal year 2020: $1.91 (loss) per share | Fiscal year 2016: $2.95 per share | Fiscal year 2015: $0.05 (loss) per share | Fiscal year 2014: $0.17 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026